JP4989638B2 - 足場 - Google Patents

足場 Download PDF

Info

Publication number
JP4989638B2
JP4989638B2 JP2008515292A JP2008515292A JP4989638B2 JP 4989638 B2 JP4989638 B2 JP 4989638B2 JP 2008515292 A JP2008515292 A JP 2008515292A JP 2008515292 A JP2008515292 A JP 2008515292A JP 4989638 B2 JP4989638 B2 JP 4989638B2
Authority
JP
Japan
Prior art keywords
peptide
stefin
scaffold
protein
stm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008515292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008541776A (ja
JP2008541776A5 (enExample
Inventor
ロビー ウッドマン
ヨハネス ツンハン ヨ
ソフィー ローレンソン
フェリーニョ ポール コ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511873A external-priority patent/GB0511873D0/en
Priority claimed from GB0608836A external-priority patent/GB0608836D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of JP2008541776A publication Critical patent/JP2008541776A/ja
Publication of JP2008541776A5 publication Critical patent/JP2008541776A5/ja
Application granted granted Critical
Publication of JP4989638B2 publication Critical patent/JP4989638B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2008515292A 2005-06-10 2006-06-08 足場 Expired - Fee Related JP4989638B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0511873A GB0511873D0 (en) 2005-06-10 2005-06-10 Scaffold
GB0511873.2 2005-06-10
GB0608836A GB0608836D0 (en) 2006-05-04 2006-05-04 Scaffold
GB0608836.3 2006-05-04
PCT/GB2006/002115 WO2006131749A2 (en) 2005-06-10 2006-06-08 Scaffold

Publications (3)

Publication Number Publication Date
JP2008541776A JP2008541776A (ja) 2008-11-27
JP2008541776A5 JP2008541776A5 (enExample) 2009-10-22
JP4989638B2 true JP4989638B2 (ja) 2012-08-01

Family

ID=37314237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515292A Expired - Fee Related JP4989638B2 (ja) 2005-06-10 2006-06-08 足場

Country Status (9)

Country Link
US (2) US8063019B2 (enExample)
EP (1) EP1904529B1 (enExample)
JP (1) JP4989638B2 (enExample)
AT (1) ATE477272T1 (enExample)
AU (1) AU2006256530B2 (enExample)
CA (1) CA2610976C (enExample)
DE (1) DE602006016133D1 (enExample)
DK (1) DK1904529T3 (enExample)
WO (1) WO2006131749A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4989638B2 (ja) * 2005-06-10 2012-08-01 メディカル リサーチ カウンシル 足場
GB0807065D0 (en) * 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
GB201302597D0 (en) * 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
JP6655074B2 (ja) * 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
CA3048486A1 (en) 2017-01-04 2018-07-12 Complete Genomics, Inc. Stepwise sequencing by non-labeled reversible terminators or natural nucleotides
EP3574326B1 (en) 2017-05-19 2025-03-19 Philip Morris Products S.A. Diagnostic test for distinguishing the smoking status of a subject
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
NZ788210A (en) * 2019-10-16 2025-11-28 Lg Chemical Ltd Neonatal fc receptor binding affimers
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022073493A1 (en) 2020-10-09 2022-04-14 Bgi Shenzhen Co., Ltd. Methods and compositions for bioluminescence-based sequencing
WO2023153876A1 (ko) * 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
WO2023182945A2 (en) * 2022-03-24 2023-09-28 Agency For Science, Technology And Research Engineering peptides using peptide epitope linker evolution
US20260022343A1 (en) * 2022-12-29 2026-01-22 Affyxell Therapeutics Co., Ltd. Genetically modified cells comprising a nucleic acid encoding a cd40l binding agent and uses thereof
GB202403780D0 (en) 2024-03-15 2024-05-01 Avacta Life Sciences Ltd Polypeptides and methods for detecting and quantifying small molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2182598C2 (ru) * 1994-11-21 2002-05-20 Новартис Аг Модифицированные ингибиторы протеиназы
ATE223971T1 (de) * 1998-07-20 2002-09-15 Inoxell As Neue methoden zum auffinden von liganden- und ziel-biomolekülen
CA2544820C (en) 2003-11-06 2014-02-18 Genencor International, Inc. Bacterial expression of protease inhibitors and variants thereof
JP4989638B2 (ja) * 2005-06-10 2012-08-01 メディカル リサーチ カウンシル 足場

Also Published As

Publication number Publication date
CA2610976A1 (en) 2006-12-14
AU2006256530A1 (en) 2006-12-14
US8063019B2 (en) 2011-11-22
EP1904529A2 (en) 2008-04-02
EP1904529B1 (en) 2010-08-11
US8481491B2 (en) 2013-07-09
DE602006016133D1 (de) 2010-09-23
CA2610976C (en) 2020-11-24
ATE477272T1 (de) 2010-08-15
JP2008541776A (ja) 2008-11-27
US20080207509A1 (en) 2008-08-28
WO2006131749A3 (en) 2007-05-18
WO2006131749A2 (en) 2006-12-14
AU2006256530B2 (en) 2012-12-20
DK1904529T3 (da) 2010-11-15
US20120190819A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
US8481491B2 (en) Scaffold polypeptides for heterologous peptide display
Woodman et al. Design and validation of a neutral protein scaffold for the presentation of peptide aptamers
US20090130676A1 (en) Interaction trap systems for detecting protein interactions
US8853131B2 (en) Modified Stefin A scaffold proteins
US20120258920A1 (en) Peptides and aptamers thereof as specific modulators of mutant p53 function
US6399296B1 (en) Interaction trap systems for detecting protein interactions
EP1248840A2 (en) Circularly permutated, interaction-activated proteins
Gonçalves et al. The proapoptotic protein Smac/DIABLO dimer has the highest stability as measured by pressure and urea denaturation
Mann et al. Enhancement of muramyl dipeptide‐dependent NOD2 activity by a self‐derived peptide
ES2350455T3 (es) Uso de estefina a como proteína de armazón.
Ghosh et al. The N-terminal lysine residue-rich domain II and the 340–430 amino acid segment of eukaryotic initiation factor 2-associated glycoprotein p67 are the binding sites for the γ-subunit of eIF2
CN120271685B (zh) 一种BiFC荧光互补对及其应用
Sacks Mechanism of Shieldin-Mediated Regulation of DNA End Resection in DNA Break Repair Pathway Choice
Manczyk Structural and Functional Characterization of Ubiquitin Variants and Ubiquitin Binding Proteins
Khandagale et al. Human DNA polymerase delta is a pentameric complex with dimeric p12 subunit: Implications in enzyme architecture and PCNA interaction
Lim Structural Elucidation of a Multifunctional Protein from Orientia tsutsugamushi
Nanji Characterizing the assembly and molecular interactions of the fission yeast Atg1 autophagy regulatory complex
Sjøgaard et al. The Arabidopsis autophagy cargo receptors ATI1 and ATI2 bind to ATG8 via intrinsically disordered regions and are post-translationally modified upon ATG8 interaction
Whitman et al. The Dissertation Committee for Gabrielle Nina Thibodeaux Certifies that this is the
Zhu Identification of Biologically Relevant Binding Targets of SH3 Domains Using a Compensatory Mutation Approach
JP2004530411A (ja) 抗菌化合物の同定方法
Spiliotopoulos et al. Discovery of peptide ligands targeting a specific ubiquitin-like domain-binding site in the deubiquitinase USP11 Anastasios Spiliotopoulos1, 2, Lia Blokpoel Ferreras1, Ruth M. Densham3, Simon G. Caulton1, Ben C. Maddison4, Joanna R. Morris3, James E. Dixon1, Kevin C. Gough2* and Ingrid Dreveny1
Hardy Role of an alpha-helical bulge and kink in the heat shock transcription factor
Westcott Structural and functional studies of Ser/Thr kinase signaling in mycobacterium tuberculosis
Wilbur Conformational switches regulate clathrin mediated endocytosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120416

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120427

R150 Certificate of patent or registration of utility model

Ref document number: 4989638

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees